Mark, given your vast experience—serving on boards of many companies and your leadership at Otsuka, where you drove successful product launches across the CNS space in Europe—what were the key market readiness lessons you learned? How do these lessons help shape commercialization roadmaps today, especially for specialized indications like inflammatory and fibrotic diseases?
Mark Altmeyer: I view launch readiness as having two principal dimensions: enduring fundamentals and evolving practices.
First, the enduring fundamentals—the things that have not changed over the years—center on building strong and meaningful relationships with Key Opinion Leaders (KOLs). When preparing to bring a new therapy to market, especially in complex areas like CNS disorders, you must begin by engaging a small, focused group of KOLs who can truly understand your product’s scientific underpinnings and its clinical profile. This engagement cannot just be a superficial acquaintance; it requires ongoing dialogue and genuine education about where your product fits in the treatment paradigm. Over time, that core group should be carefully expanded, incorporating more experts who can become advocates for the therapy. These individuals will not only inform their peers but also help you anticipate how your product will be perceived in real-world clinical practice, which is invaluable.
Another closely linked point of launch readiness is your product positioning and, especially, your messaging. This is more than just a list of features or mechanisms of action. You need to distill your offering down to four or five essential messages that physicians, payers, and other key stakeholders can immediately grasp. Those points should answer critical questions: What makes this product different? Why is it meaningful compared to established alternatives? For which patient populations does it make the biggest difference? And at what point in the treatment journey should clinicians consider it? These pillars of messaging must be clear, compelling, and consistently reinforced across all channels.
Now, regarding the practices that have changed—and these shifts are accelerating— we must recognize how physician access and channel strategies have evolved. Traditional, in-person engagement is not as feasible as it once was, owing to time constraints and restrictions on sales representatives in clinics and hospitals. Instead, digital engagement through omnichannel approaches has become paramount. We can now reach physicians and patients more effectively through targeted social media campaigns, disease-specific online communities, webinars, and virtual events that were inconceivable or far less effective five or ten years ago.
Moreover, our ability to identify, segment, and communicate directly with patient populations has dramatically improved thanks to advances in data analytics. Through platforms like Google and Facebook, we can zero in on individuals with rare or particular disease profiles and ensure that they and their doctor receive relevant information quickly. To match these new opportunities, companies are reallocating promotional budgets and resources towards digital outreach, content marketing, and education that is both personalized and scalable.
In short, the commercialization roadmap is built upon proven fundamentals but now incorporates digitally driven tactics that allow for more precise, flexible, and impactful execution at every stage of launch.
When a commercial launch does not meet expectations or falls short, how do you diagnose what went wrong? What factors do you consider in assessing the underlying challenges?
Mark Altmeyer: Diagnosing underperformance in a commercial launch is rarely simple, and if you discover significant issues late in the process, it can be tough to recover without significant course correction. Therefore, it’s vital to continuously monitor all key metrics and feedback channels from day one.
There are three primary areas I scrutinize when facing launch challenges: strategy, messaging, and execution.
- Strategy: Is the product positioned appropriately for the intended market? Are we targeting the right patient demographics and clinical segments? If the strategy is misaligned with market realities, even the strongest product may struggle.
- Messaging: I ask whether the message is truly resonating with doctors and other stakeholders. Are the value propositions clear and memorable? Do physicians understand how this therapy fits compared to existing standards of care?
- Execution: Finally, I look closely at the operational side. Are sales teams and medical liaisons able to access target doctors? Is the frequency and quality of engagement sufficient? Are there external barriers—such as restrictive hospital policies or payer roadblocks—that are preventing progress? If execution is lacking, even a well-crafted strategy and clear message may fail.
Feedback from the field—sales representatives, medical affairs, and even directly from clinicians—is essential to pinpoint where breakdowns may be occurring. Sometimes the issue is simple, such as limited access to physicians due to logistical barriers. Other times, you might find that the product’s differentiation was not adequately communicated, or its clinical relevance wasn’t translated into practical guidance for prescribers.
In sum, continual assessment and willingness to adjust in real-time are critical. Addressing challenges early, whether by refining the message or re-aligning strategic priorities, increases the odds of regaining traction and achieving success.
With scientific advancements, there is an increased understanding of overlooked biological contributors to chronic inflammation and fibrotic diseases. How do these insights inform your view of unmet needs and therapeutic opportunities—what you might call “white space”—in inflammatory indications?
Mark Altmeyer: The landscape of inflammatory and fibrotic diseases is transforming, driven by discoveries in disease biology. As we uncover the complex interplay of molecular and cellular contributors to chronic inflammation, we realize how many therapeutic gaps persist—these represent substantial “white space” in medicine.
For example, many inflammatory disorders are still managed with broad immunosuppression, which can be effective but often comes with significant side effects and limited long-term disease modification. With emerging knowledge of previously overlooked pathways and cell types involved in disease initiation and progression, there is now potential to target the root causes more precisely.
This evolving understanding is prompting companies to prioritize research around novel mechanisms, biomarkers, and patient subtypes that could be amenable to differentiated therapy. It means investing in clinical programs that go beyond symptom control and strive for true disease modification or remission. The greatest opportunities, then, lie in developing therapies that offer clear clinical value where none currently exists—whether through more targeted biologics, gene therapies, or innovative small molecules.
Importantly, the voice of patients and treating physicians is now more central in defining these unmet needs, thanks to better data collection and engagement channels. We can rapidly pinpoint not only where scientific advances are opening doors, but also where patient communities are calling for new solutions. This feedback loop between science and market need shapes pipeline decisions and accelerates the pursuit of innovative products with the highest impact.
What are your best practices for designing early-phase clinical studies, especially Phase II, to make assets attractive for strategic partnerships or future transactions with larger pharmaceutical companies?
Mark Altmeyer: Designing a Phase II study is not just a matter of scientific rigor; it requires foresight into how the generated data will be perceived and valued by potential partners or acquirers. My approach is to think early about the “transactability” of both the asset and the study itself.
First, focus on endpoints and patient populations that will be meaningful for both regulatory approval and commercial success. For example, choosing endpoints that demonstrate not just statistical significance, but real clinical relevance, improves the asset’s attractiveness in partnership discussions.
Second, design protocols so they clearly differentiate your product from existing therapies. If your data set can illustrate meaningful advantages—safety, efficacy, patient-reported outcomes, or even cost-effectiveness—that are easy for a strategic partner to understand and validate, the likelihood of a transaction goes up enormously.
Third, invest in robust and transparent data collection. Clean, credible, and well-analyzed data is essential. Large partners will dissect the study in detail; any ambiguity or gaps may undermine interest.
Finally, think about the right balance of risk and proof-of-concept. A Phase II that is ambitious enough to show true promise, but also designed to mitigate operational and regulatory risk, sends a message that the asset and team are ready for further development or collaboration.
In sum, I advise companies to approach study design as both a scientific and a strategic exercise, aligning early choices with the kinds of evidence strategic partners value in evaluation and eventual deal-making.
Industry networks and professional relationships seem influential in commercialization success. In your experience, how do these connections affect strategy execution and long-term outcomes?
Mark Altmeyer: Industry is fundamentally built on relationships across companies, disciplines, and even regulatory bodies. Longstanding professional networks grant access to expertise, perspectives, and operational experience that no company can develop in isolation.
When launching a product or exploring a partnership, trusted collaborators can help you navigate obstacles, identify opportunities, and solve complex challenges quickly. Knowledge-sharing among colleagues from past roles—from places like Otsuka, Pfizer, Merck, and various biotech start-ups—means you have a ready base of insight for refining strategies and troubleshooting execution issues as they arise.
Additionally, robust networks foster credibility with external stakeholders. When a KOL or industry leader is willing to advocate for your product, or when teams have a proven history of successful collaboration, the path to physician acceptance, regulatory trust, and partnership negotiations becomes much smoother.
Consequently, I recommend that professionals invest constantly in building and sustaining these relationships. The strength of your network often dictates the speed and depth at which you can respond to challenges and capitalize on market opportunities. In the end, commercialization is not just about product and data; it is about the people and trust who enable its success.
Summary Statement:
Mark Altmeyer’s responses encapsulate decades of learning: successful commercialization of therapies in CNS and inflammatory spaces demands a dual emphasis on foundational relationships and messaging, as well as a willingness to embrace new digital engagement and precision strategies. Forward-thinking clinical development, robust data, and trust-based industry relationships are pivotal, creating the bridge from innovation to real-world adoption, advancing patient care, and driving long-term business growth.
Bios:
Mark Altmeyer: Current Board member at Aculys, Alector, AM Pharma, Calluna Merz, and Novaremed. Previously, Mark was the founder, Chief Executive Officer, and Board Member of Arvelle. He has 30 years of experience leading successful drug commercialization efforts as a pharmaceutical executive, with a focus on therapies for central nervous system (CNS) disorders. He was previously President and Chief Commercial Officer at Axovant. Prior to that, Mark was Chief Executive Officer and President of Otsuka America Pharmaceutical, Inc., where he led a team of 1,700 employees and helped grow the company’s revenue from $2.6 billion to over $5 billion. He led the launch of Abilify®, the top-selling CNS drug in history and the number-one selling drug in the United States in 2013. Earlier in his career, Mr. Altmeyer held a number of executive leadership roles at Bristol-Myers Squibb, including Senior Vice President, Global Commercialization, and Senior Vice President, Neuroscience Business Unit. Mr. Altmeyer received an M.B.A. from Harvard Business School and a B.A. in economics from Middlebury College.
Partha Anbil is a Contributing Writer for the MIT Sloan Career Development Office and an alumnus of MIT Sloan. Besides being VP of Programs of the MIT Club of Delaware Valley, Partha is a long-time life sciences consulting industry veteran. He is a Senior Advisor to NextGen Invent Corporation, an AI, Data Analytics, and digital transformation company, as well as to AI startups such as EcotoneAi, MediQlogix, and AlmaAi. He has held senior leadership roles at IBM, Booz & Company (now PWC Strategy&), IMS Health Management Consulting Group (now IQVIA), and KPMG.
Michael Wong is a Contributing Writer for the MIT Sloan Career Development Office and an Emeritus Co-President and board member of the Harvard Business School Healthcare Alumni Association. Michael is a Part-time Lecturer for the Wharton Communication Program at the University of Pennsylvania, and his ideas have been shared in the MIT Sloan Management Review and Harvard Business Review.
